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Objectives: The increased use of central venous access primarily for hemodialysis has led to a significant increase in clinically
relevant central venous occlusive disease (CVOD). The magnitude of and the optimal therapy for CVOD are not clearly
established. The purpose of this study is to define the problem of CVOD and determine the success of percutaneous
therapy for relieving symptoms and maintaining central venous patency.
Methods: Patients presenting with disabling upper-extremity edema suggestive of central venous stenosis or occlusion
during a 3-year period were evaluated by venography of the upper extremity and central veins. Percutaneous venous
angioplasty (PTA) and/or stent placement was performed as clinically indicated. The success of therapy was assessed, and
the patients were observed to determine the incidence of recurrence and additional procedures. Recurrent lesions
underwent similar evaluation and treatment.
Results: A total of 32 sides were treated in 29 patients with a mean of 1.9 interventions per side treated. Hemodialysis-
related lesions were the underlying cause in 87% with the remaining 13% related to previous central venous catheteriza-
tion. The lesions involved the axillary, subclavian, and innominate veins with complete venous occlusion in six (19%)
cases. Percutaneous angioplasty was followed by stent placement in six (19%) cases. The procedure was a technical success
and was performed without complications in all cases (100%). Mean follow-up was 16.5 months (range, 4-36 months).
On average, patient symptoms were controlled for 6.5 months after the initial intervention. Recurrent edema led to
additional PTA in 20 (63%) cases. Fifty percent (n  14) of patients with an arteriovenous fistula (AVF) experienced
recurrent symptoms after initial and/or repeat PTA and required AVF ligation. Complete resolution after the initial PTA
was predictive of long-term success.
Conclusions: Central venous occlusive disease has emerged as a significant clinical problem. Percutaneous venous
angioplasty can provide temporary symptomatic relief; however, multiple procedures are often required and long-term
relief is rarely achieved. (J Vasc Surg 2004;39:578-82.)
The optimal therapy for symptomatic central venous
occlusive disease (CVOD) is not clearly defined. Both
endovascular and open procedures have been used for the
treatment of central venous stenoses and occlusions, but
neither approach is accepted as the standard of care. There
are numerous etiologies of symptomatic lesions; however,
they most commonly result from prolonged central venous
catheterization in the setting of end-stage renal disease
(ESRD) and ipsilateral arteriovenous fistula (AVF). Lesions
can also occur in the venous outflow of an AVF without
previous catheterization.1-3 Venous hypertension can de-
velop and is commonly associated with chronic pain and
edema in the affected extremity.
Although symptomatic relief is frequently accom-
plished by fistula ligation, this approach can sacrifice a
functional fistula in cases in which alternative access sites
are limited. Surgical reconstructive procedures that
maintain or restore central venous flow can effectively
control the edema and allow for AVF preservation. How-
ever, patency rates have not been significantly better than
with endovascular techniques and extensive reconstruc-
tions might not be advisable in a group of patients with
multiple comorbidities.4-6 Percutaneous venous angio-
plasty (PTA) provides a minimally invasive alternative to
surgery. In previous series an acceptable rate of AVF
salvage along with symptomatic relief has been report-
ed.1,6 Several studies suggest that PTA combined with
venous stenting for both peripheral and central venous
lesions improves the success with better long-term pa-
tency. However, this improvement has not been con-
firmed, and the long-term outcome of central venous
stents is undefined.1,6-9
At our institution central venography and PTA are used
routinely for the diagnosis and treatment of symptomatic
CVOD. Clinical success is defined by resolution of pain and
edema along with preservation of the AVF. Although we
commonly use venography and PTA for the management
of peripheral venous lesions and failing AVFs, the current
study was undertaken to define the clinical success of this
approach for the treatment of symptomatic central venous
stenoses and occlusions associated with significant and dis-
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abling upper-extremity edema. Lesions associated with
both an ipsilateral AVF and/or previous central venous
catheterization were evaluated.
METHODS
A retrospective analysis was performed of patients pre-
senting during a 3-year period with disabling upper-ex-
tremity edema consistent with central venous stenosis or
occlusion. Disabling edema was associated with local symp-
toms of pain and arm heaviness that resulted in a functional
limitation of the extremity and precluded normal daily
activities. Patients underwent upper-extremity and central
venography, and only those patients with at least one
central venous lesion were included. All medical records
were reviewed for demographic and clinical data. Previous
procedures, comorbidities, and the severity of the edema
were documented and entered into a database.
Details of the intervention were obtained by a review of
the operative notes and venograms (Fig). The location of
the lesion and size of the angioplasty balloon used for final
dilation were noted. Our current standard is two inflations
for 2 to 3 minutes with systemic heparinization prior to
balloon inflation. Technical success of PTA was routinely
defined by completion venography in two views demon-
strating less than 30% residual stenosis. Venous pressure
measurements were not performed. Angioplasty is usually
followed by stent placement for lesions with greater than a
30% residual stenosis. We prefer self-expanding stents over
balloon-expandable stents in the venous system. Patients
were typically discharged on the day of the procedure after
clinical assessment. Long-term anticoagulation or anti-
platelet therapy was not prescribed.
Patients were assessed during routine follow-up with
clinical success defined by an improvement in symptoms.
The response to PTA was classified as complete (no or
minimal residual symptoms/edema), partial (improvement
with moderate residual symptoms/edema), or minimal (no
appreciable change in symptoms/edema). Arm circumfer-
ence measurements were not routinely performed. The
duration of the symptom-free period was determined from
patient history and physical examination by an attending
vascular surgeon. In cases of an ipsilateral AVF, the status of
the fistula was noted at each time point. Failure was defined
by recurrence of symptoms that lead to repeat venography
and PTA. Alternatively, recurrent symptoms in some cases
necessitated surgical intervention with AVF ligation. The
end point for each patient was reached at the time of fistula
ligation, maximal follow-up, or patient death. Surgical by-
pass graft was considered in each patient but was not
performed on the basis of unsuitable anatomy or poor
overall patient condition; therefore, surgical reconstruction
did not define an end point.
The primary and secondary periods of symptomatic relief
were calculated by using survival curves by life table analysis.
The incidence of time-dependent variables during follow-up
was compared by using the log-rank test. Subgroup analysis
was performed on the basis of the response to the initial PTA.
Baseline and follow-up of discrete variables for the groups
were compared by using both the2 test and Fisher correction
for small subgroups. Continuous variables were compared by
using the Mann-Whitney U test. The odds ratio (OR) and
relative risk (RR) for each variable to predict future interven-
tions in each group was calculated where appropriate. P .05
was accepted as clinically significant.
A, Axillary vein stenosis. B, Technical success following PTA.
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RESULTS
Patients. Ninety-four patients underwent PTA during
the study period. The current study represents a subgroup
of 29 patients that presented with symptomatic CVOD
defined by upper-extremity edema. A total of 32 sides were
evaluated as three patients had treatment of bilateral le-
sions. Follow-up was available for each patient with a mean
of 16.5 months (range, 4-36 months) for each side treated.
There were 18 men and 11 women with a mean age of
67.2 years. In 28 (87%) of the lesions there was an ipsilateral
arteriovenous fistula (n  18) or graft (n  10). Twenty-
one of these had previously undergone ipsilateral central
venous catheterization. The remaining four (13%) lesions
were associated with previous central venous catheteriza-
tion unrelated to dialysis. No patient in the current study
had a history of pacemaker insertion.
Lesion characteristics and initial results. All proce-
dures were performed percutaneously. There were 19 le-
sions on the right and 13 on the left. The lesions were most
commonly located in the subclavian vein. It was involved in
17 (53%) cases followed by the innominate vein in 11
(34%), axillary vein in 3 (9%), and superior vena cava in 1
(3%). The location was not predictive of procedural success
or failure.
The degree of stenosis was greater than 50% in all cases.
Segmental occlusion of the affected vein was present in 6
(19%) cases. Initial percutaneous angioplasty was techni-
cally successful in 26 (81%) of 32 cases. Suboptimal results
from PTA led to stent placement in the remaining six (19%)
cases. Self-expanding stents were used to successfully treat
these 6 residual lesions. The overall technical success rate of
PTA and PTA combined with stent placement was 100%.
The size of the balloon for final dilation was as follows: 7
mm (n  1), 8 mm (n  4), 10 mm (n  3), 12 mm (n 
11), 14 mm (n 12), and 16 mm (n 1). Balloon length
ranged from 2 to 4 cm with inflation pressures of 6 to 20
ATM. There were no procedure-related complications at
the access site, venous perforations, or deaths.
Long-term results. A single PTA was performed for
12 (37%) lesions, whereas recurrent edema requiring fur-
ther intervention occurred in 20 limbs (63%). On average,
1.9 (range, 1-4) interventions were performed for each side
treated. Of the patients with an AVF, 50% (n  14)
required fistula ligation for control of symptoms. Surgical
bypass graft was considered but not performed in these
patients because of unsuitable anatomy and/or a high
surgical risk with a poor long-term prognosis. One patient
died during the study. In the remaining 17 cases, the
patient’s symptoms were controlled at the completion of
the study.
A complete response to the initial PTA occurred in 15
patients. One patient in this group died and one required
AVF ligation. The end point for the remaining 13 patients
was maximal follow-up (mean  18.1 months). Three of
these lesions were not related to dialysis. Eleven patients
had a partial response to the initial PTA with an end point
of AVF ligation in 8 and maximal follow-up in 3 (mean 
9.0 months). One lesion in this group was not related to
dialysis. The remaining six patients had minimal improve-
ment after PTA. Fistula ligation was required in five of six
patients. The end point for the remaining patient was
maximal follow-up at 4.2 months.
Predictors of success. The 32 lesions were divided
into two groups on the basis of the resolution of the edema
after the initial PTA: complete resolution (n  15) and
partial or minimal resolution (n  17). A comparison
between the two groups is found in the Table. The primary
and secondary symptom-free periods were significantly
longer in the group with complete resolution after the
initial PTA. Only 1 (8%) of the 12 patients in this group
with an AVF required ligation for symptomatic control
during the study period compared with 13 of 16 patients
(81%) in the group with a partial or minimal response to the
initial PTA. The odds of requiring AVF ligation (when
present) was significantly greater in the later group (OR 
41.6). Three patients in this group underwent fistula liga-
tion without repeat PTA. Repeat PTA was required less
frequently for symptomatic control in the group with a
complete response after the first PTA (40% versus 82%). At
the completion of the study, 13 (86%) of the cases in this
group were asymptomatic with a functioning AVF (when
present) compared with only 4 cases (23%) in the other
group. The chance of being asymptomatic without AVF
ligation at the completion of the study was significantly
greater in the group that had a complete initial response
(RR, 3.9).
Comparison of two groups and predictors of success
All
(n  32)
Complete
response*
(n  15)
Partial/minimal
response*
(n  17) P
Primary symptom-free period 6.5 mo 8.1 mo 4.0 mo .05
Secondary symptom-free period 13.6 mo 15.1 mo 12.2 mo .05
Repeat PTA 20 (63%) 6 (40%) 14 (82%) .05
PTA no. 1.9 1.4 2.6 .05
Ligation AVF (when present) 14 (50%) 1 (8%) 13 (81%) .05
Stent 6 (19%) 2 (12%) 4 (23%) NS
Occlusion 6 (19%) 2 (12%) 4 (23%) NS
*Response to initial PTA.
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Subgroup analysis was performed of the lesions treated
by stenting (n 6). The primary and secondary symptom-
free period was 6.5 and 13.5 months, respectively, and was
similar (P .05) to the symptomatic relief for the group as
a whole (6.5 and 13.6 months). Repeat PTA was required
in five cases (83%), and in four cases (67%) ligation of an
ipsilateral AVF was needed to control the symptoms. Stent-
ing did not reduce the number of interventions required to
provide symptomatic relief (mean, 3.0/side treated).
The group of lesions not related to dialysis (n 4) were
also analyzed separately. The primary and secondary symp-
tom-free periods were 10.4 and 17.1 months, respectively.
Three of four patients had a complete response after the
initial PTA. One patient had a partial response and required
repeat PTA.
DISCUSSION
Symptomatic CVOD has emerged as a significant clin-
ical problem. At our institution this problem has paralleled
the increased use of long-term central venous access and
upper-extremity AVF creation in patients with ESRD. The
primary goal in this setting is to provide symptomatic relief
for the patient while maintaining function of the associated
AVF when present.5 Endovascular techniques, including
PTA, have gained popularity for the initial treatment of
symptomatic CVOD.1,4-6 The goal of the current study
was to review our experience with PTA for symptomatic
lesions and to determine the effectiveness of this approach
for controlling symptoms and maintaining AVF patency.
Previous reports have documented that PTA provides
acceptable results for the initial treatment of symptomatic
CVOD.1,4,6,9 The technical success of PTA in the current
study was greater than 80% and is similar to other studies.
When combined with stent placement, the technical suc-
cess of the initial procedure increased to 100%. In addition,
the endovascular procedures were performed with no major
complications and no deaths.
Although it is a standard in the vascular literature to
report on the patency of a vessel after a given intervention,
our study focuses primarily on the clinical success of PTA
for relieving symptoms associated with CVOD. We rarely
perform duplex ultrasound scanning to document patency
or occlusion in this setting, because it does not alter our
plans for venography to assess for recurrent lesions. Many
of the patients in our series had an initial improvement in
their symptoms after PTA and were able to continue dial-
ysis in the affected extremity. As pointed out by others,
extending the “life” of a functional AVF can have a major
effect on the quality of life for a patient dependent on
dialysis when alternative access sites are limited.1,4,7,8
Similar to other investigators, we found that initial PTA
for symptomatic CVOD at best provides temporary relief in
most patients.1,7-10 Almost three fourths of our patients
required additional interventions(s) for the management of
recurrent edema. In many cases, PTA for recurrent lesions
evolved into a form of maintenance or palliative therapy to
provide symptomatic relief. Our patients chose repeat PTA
versus open surgical reconstruction because of the advan-
tages associated with the minimally invasive procedure and
because the success of surgery and repeated PTA have been
shown to be similar.4 Despite the success of additional
interventions, 50% of the patients with an AVF eventually
required ligation for symptomatic relief.
To our knowledge, the clinical and procedural factors
associated with the success of PTA have not been previously
identified. Despite the overall poor long-term outcome of
PTA for controlling edema and maintaining fistula patency,
several factors in our study were predictive of success. Most
notable, long-term symptomatic relief was significantly im-
proved if there was complete resolution of the symptoms
after the initial PTA compared with partial or minimal
resolution. In cases in which a complete response to PTA
occurred both the recurrence rate and the average number
of PTAs required to maintain symptomatic relief was less.
In addition, the chance of requiring AVF ligation was
reduced, and the overall likelihood of being symptom free
was increased compared with those cases in which partial or
minimal response to the initial PTA occurred. Although
not pointed out in previous reports, it will be interesting to
see whether future studies confirm our observation that the
initial response to PTA is predictive of long-term success.
It may be argued that stent placement after PTA might
improve patency rates in central venous lesions. However,
previous reports fail to conclusively demonstrate that stent-
ing provides additional benefit. Quinn et al9 compared
PTA and stenting in both peripheral and central lesions and
found that the patency rates in central lesions were equal at
1 year. A report by Oderich et al7 suggests that stenting
improves the long-term results for central venous lesions;
however, the primary patency (22% at 1 year) and re-
intervention rate (60%) is no better than our results. Similar
to our findings, Kalman et al6 found that the addition of
stenting to PTA did not improve the results in that series.
In addition, placement of the stent in the deep venous
system may complicate the situation if future surgical re-
construction is required. Stents were used to treat 6 of the
32 lesions in our study. They were only used when the
results by PTA were clearly suboptimal for achieving a
technical success at the initial procedure. Stenting did not
extend the symptom-free period or prevent surgical inter-
vention compared with PTA alone in our series. Our study
does not provide an explanation of the poor results associ-
ated with stenting. Further experience with stenting in the
central venous circulation might further clarify the indica-
tions for stent placement. However, on the basis of the
current literature, the success of PTA is improved by no
more than 10% to 15% with the addition of stenting. The
increased expense, potential complications, and marginal
benefit associated with stenting do not appear justified,
and, at this point, the practice of routine stent deployment
for central venous lesions should be avoided.
It could be argued that some of the patients in the
current study were appropriate candidates for surgical by-
pass grafting. We have performed venous bypass graft pro-
cedures in this setting; however, the number of reconstruc-
tions performed at our institution has decreased in recent
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years secondary to the emergence of endovascular therapy
and the morbidity of surgery in this group of high-risk
patients. Bhatia et al5 reported a 31% mortality at 1 year in
their study of patients with ESRD and CVOD. In addition,
the duration of symptomatic relief provided by bypass graft
compared with that PTA followed by repeat PTA for recur-
rent symptoms has been previously documented and dem-
onstrated to be similar.4
Although surgical reconstruction was considered, the
primary reason that none of the patients in this series
underwent bypass graft was related to anatomic factors. We
have found that the internal jugular vein is often diseased
and not suitable for use as a venous outflow in the com-
monly described jugular venous turn-down procedure. Be-
cause the occlusive disease is often located in the more
central veins such as the innominate, extensive reconstruc-
tions requiring thoracotomy are often required to bypass
the disease. It is our philosophy that a major venous recon-
struction is rarely indicated in a group of high-risk patients
with a limited life expectancy, as long as other access sites
are available.
There are several limitations of the current study. Most
notable, the patency of the vein was not assessed by objec-
tive methods in all patients. Regardless of the patency,
however, the success of PTA for providing symptomatic
relief is the goal of the procedure and ultimately determines
procedural success. Our study is also limited by its retro-
spective nature and inconsistent follow-up of this patient
population. Despite these limitations, we believe the results
are an accurate reflection of what could be expected in the
clinical setting.
CONCLUSION
Percutaneous central venous angioplasty could provide
temporary symptomatic relief in patients that present with
central venous stenosis and upper-extremity edema. Com-
plications from PTA are infrequent. It offers a minimally
invasive, first-line approach for a difficult problem in a
patient population with significant comorbidities. How-
ever, the durability of PTA is limited, and in most patients
additional interventions are required to extend the symp-
tom-free period. The long-term results from PTA are im-
proved in cases in which complete resolution of the edema
occurs after the initial intervention. If partial or minimal
symptomatic relief is achieved with initial PTA, most pa-
tients with an associated AVF ultimately require fistula
ligation for long-term symptomatic relief.
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